AstraZeneca_NNP Annual_JJ Report_NNP and_CC 106_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 19_CD RESERVES_NNS CONTINUED_VBD Nature_NN and_CC purpose_NN of_IN other_JJ reserves_NNS The_DT other_JJ reserves_NNS arose_VBD from_IN the_DT cancellation_NN of_IN 1,255_CD m_NN of_IN share_NN premium_NN account_NN by_IN the_DT parent_NN company_NN in_IN 1993_CD ._.
The_DT reserve_NN was_VBD available_JJ for_IN writing_VBG off_RP goodwill_NN arising_VBG on_IN consolidation_NN and_CC ,_, subject_JJ to_TO guarantees_NNS given_VBN to_TO preserve_VB the_DT rights_NNS of_IN creditors_NNS as_IN at_IN the_DT date_NN of_IN the_DT court_NN order_NN ,_, is_VBZ available_JJ for_IN distribution_NN ._.
The_DT cumulative_JJ amount_NN of_IN goodwill_NN written_VBN off_RP directly_RB to_TO reserves_NNS resulting_VBG from_IN acquisitions_NNS ,_, net_NN of_IN disposals_NNS ,_, amounted_VBD to_TO $_$ 714m_CD 2004_CD $_$ 675m_CD ,_, 2003_CD $_$ 656m_CD using_VBG year_NN end_NN rates_NNS of_IN exchange_NN ._.
There_EX are_VBP no_DT significant_JJ statutory_JJ or_CC contractual_JJ restrictions_NNS on_IN the_DT distribution_NN of_IN current_JJ profits_NNS of_IN subsidiaries_NNS ,_, joint_JJ ventures_NNS or_CC associates_NNS :_: undistributed_JJ profits_NNS of_IN prior_JJ years_NNS are_VBP ,_, in_IN the_DT main_JJ ,_, permanently_RB employed_VBN in_IN the_DT businesses_NNS of_IN these_DT companies_NNS ._.
The_DT undistributed_JJ income_NN of_IN AstraZeneca_NNP companies_NNS overseas_RB may_MD be_VB liable_JJ to_TO overseas_JJ taxes_NNS and_CC or_CC UK_NNP taxation_NN after_IN allowing_VBG for_IN double_JJ taxation_NN relief_NN if_IN they_PRP were_VBD to_TO be_VB distributed_VBN as_IN dividends_NNS see_VBP Note_NN 4_CD ._.
20_CD MINORITY_NN INTERESTS_NNS 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN beginning_NN of_IN year_NN 93_CD 89_CD 64_CD Minority_NNP interest_NN share_NN of_IN profit_NN 18_CD 19_CD 22_CD Actuarial_NNP gain_NN losses_NNS ,_, net_NN of_IN tax_NN 3_CD 1_CD Dividends_NNPS to_TO minority_NN interests_NNS 6_CD 1_CD Other_JJ movements_NNS including_VBG exchange_NN 14_CD 13_CD 3_CD At_IN end_NN of_IN year_NN 94_CD 93_CD 89_CD 21_CD DIVIDENDS_NNP TO_TO SHAREHOLDERS_NNS 2005 2004 2003_CD Per_IN Per_IN Per_IN 2005 2004 2003_CD share_NN share_NN share_NN $_$ m_CD $_$ m_CD $_$ m_CD Final_NNP ,_, paid_VBD 21_CD March_NNP 2005_CD $_$ 0.645_CD $_$ 0.540_CD $_$ 0.470_CD 1,061_CD 914_CD 808_CD Interim_NNP ,_, paid_VBN on_IN 19_CD September_NNP 2005_CD $_$ 0.380_CD $_$ 0.295_CD $_$ 0.255_CD 615 494 436_CD $_$ 1.025_CD $_$ 0.835_CD $_$ 0.725_CD 1,676_CD 1,408_CD 1,244_CD The_DT second_JJ interim_JJ dividend_NN ,_, to_TO be_VB confirmed_VBN as_IN final_JJ ,_, is_VBZ $_$ 0.92_CD per_IN share_NN and_CC $_$ 1,455_CD m_NN in_IN total_NN ._.
This_DT will_MD be_VB payable_JJ on_IN 20_CD March_NNP 2006_CD ._.
On_IN payment_NN of_IN the_DT dividends_NNS ,_, exchange_NN losses_NNS of_IN $_$ 41m_CD 2004_CD gains_NNS of_IN $_$ 30m_CD ,_, 2003_CD gains_NNS of_IN $_$ 22m_CD arose_VBD ._.
These_DT exchange_NN gains_NNS and_CC losses_NNS are_VBP included_VBN in_IN finance_NN expense_NN ._.
22_CD DISPOSAL_NNP OF_IN BUSINESS_NNP OPERATIONS_NNPS 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Non-current_JJ assets_NNS 270_CD Current_JJ assets_NNS 17_CD 34_CD Current_JJ liabilities_NNS 7_CD 17_CD Book_NN value_NN of_IN net_JJ assets_NNS disposed_VBD 12_CD 87_CD Disposal_NN costs_NNS 72_CD Profit_NN on_IN disposals_NNS 274_CD Less_RBR :_: Cash_NN and_CC cash_NN equivalents_NNS included_VBD in_IN undertakings_NNS disposed_VBD 3_CD 7_CD Consideration_NNP received_VBD 355_CD 80_CD The_DT cash_NN consideration_NN in_IN 2004_CD is_VBZ in_IN relation_NN to_TO the_DT sale_NN of_IN the_DT Groups_NNS share_NN of_IN the_DT joint_JJ venture_NN Advanta_NNP BV_NNP ,_, which_WDT was_VBD completed_VBN on_IN 1_CD September_NNP 2004_CD $_$ 284m_CD and_CC the_DT disposal_NN of_IN the_DT Durascan_JJ business_NN in_IN the_DT first_JJ half_NN of_IN 2004_CD $_$ 71m_CD ._.
The_DT profit_NN on_IN disposal_NN is_VBZ stated_VBN after_IN transaction_NN costs_NNS and_CC warranty_NN provisions_NNS ._.
The_DT consideration_NN received_VBN in_IN 2003_CD was_VBD in_IN relation_NN to_TO the_DT sale_NN of_IN Marlow_NNP Foods_NNP Limited_NNP ._.
